Mr. Rader is best known as the author and publisher of BIOPHARMA: Biopharmaceutical Products in the U.S. and European Markets, still the only information resource/reference concerning biopharmaceuticals (now an online Web database covering up to 2011/12; last printed book version was 6th edition, 2 vol., 1602 pages, Sept.  2007).  He is also author/publisher of the Biosimilars/Biobetters Pipeline Directory, currently an online subscription database.  For BioPlan Associates, Mr. Rader developed information resources including the Top 1000 Global Biopharmaceutical Facilities Index, a database tracking all bioprocessing facilities worldwide and their bioprocessing capacity. 

For 15 years, from 1988-early 2003 (>5,500 pages), Mr. Rader was the author and publisher of the Antiviral Agents Bulletin, the only periodical specializing in antiviral/HIV drug and vaccine development.  For over 5 years, he was Editor, BioINVENTION, a monthly U.S. biotechnology patent abstracts and news publication, with PMA (now PhRMA) then commissioning and publishing derived annual biotech patent analyses. Other books he authored include Biopharmaceutical Expression Systems and Genetic Engineering Technologies: Current and Future Manufacturing Platforms (365 pages, Oct.  2008), still the only directory of genetic engneering technologies available for licensing.  In 1994, he authored and published the Federal Bio-Technology Transfer Directory, a 678-page book further marketed as an online database until 2000, abstracting and indexing all federal, e.g., NIH, inventions and technology transfers in biotech/biomedical areas. 

From 1985-1990, Mr.  Rader was Manager of Information Services, Porton International plc, providing information and market/technology analyses for what was then the world's largest privately-held biotechnology company, and publishing through its OMEC International subsidiary.  Prior to that he served as a biomedical/chemical information specialist/manager/analyst with companies including Gillette Medical Evaluation Labs., Gillette Co.; MITRE Corp.; Biospherics; Computer Sciences Corp.  (CSC); Technical Resources Inc.; and Bio-Conversion Labs.

Earlier information resources, periodicals and studies authored by Mr. Rader include:

• BIOPHARMA: Biopharmaceuticals in the U.S. and European Markets, archived, but remains the only reference/information resource specializing in biopharmaceutical products. Last printed as a 1,600+ page book (with <10 pt. Times font), now a much larger online database.
• Antiviral Agents Bulletin, a monthly 32-page newletter about antiviral drug and vaccine development, 1987-2003 (15 years), >5,300 pages
• BioINVENTION, a U.S.  biotechnology patent abstract and news periodical; Editor, 1985-1990
• Biopharmaceutical Expresssion Systems and Genetic Engineering Technologies:  Current and Future Manufacturing Platforms, the only directory of expression systems, cell lines, vectors and other genetic engineering technologies (available for licensing)
• Federal Biotechnology Information Resources Directory; lead author/editor
• Federal Biotechnology Programs Directory; lead author/editor
• Survey of Compounds Which Have Been Tested for Carcinogenic Activity [Chemical Editor]
• "Analysis of U.S. Biotechnology Patents," issued annually, 1986-1988, by the Pharmaceutical Manufacturers Association (PMA, now PhRMA).
• Structure and Activity Search System (SANNS); Chemical Evaluation Search and Retrieval System (CESARS), Thermodynamics and other other user guides for component databases of the NIH/EPA Chemical Information System (NIH/EPA CIS).
• Chemical Information Resources Directory, NTIS, 673 pages

Published articles include:

• "Bioprocessing Year In Review:  11 Key Trends Accelerated By Covid-19," Pharmaceutical Online and Outsourced Pharma, Dec. 11, 2020.
• "Cellular and Gene Therapies Face a Manufacturing Capacity Crunch," BioPharm Intl., Sept. 1 2020, p. 46-50.
• "COVID-19's Impact On Bioprocessing: Insights From Industry Leaders," Guest Column, BioProcess Online, Aug. 5, 2020.
• "Covid-19 Impact on Bioprocessing: Accelerating Trends - Long-term Impact of Novel Coronavirus-19 on Biomanufacturing and Bioprocess Supply Chain," White Paper, BioPlan Associates, July 2020, 16 pages.
• "Biosimilars Pipeline and Market Trends," eBook/printed insert, BioProcess International, June 2020, 11 pages.
• "Covid 19: Impact on Bioprocessing and Outsourcing," Contract Pharma, May 5, 2020.
• "TOP 15 Trends in Biopharmaceutical Manufacturing, 2020," White Paper, BioPlan Associates, April 2020, 35 pages.
• "2019 FDA Biopharmaceutical Approvals: A Record Year for Follow-on Products, But is Innovation Lagging?," White Paper, BioPlan Associates, Jan. 2020.
• "The next decade of cleanrooms: Pre-fab and modular cleanrooms are on the rise, but stick-built still dominate," Pharma Manufacturing, Dec 06, 2019.
• "Bioprocessing Facilities and FDA Inspection Problems," Biopharm Intl., 32(5), May 1, 2019, p. 12-15.
• "Biosimilars Pipeline Shows Remarkable, Sustained Growth," BioProcess Online (and Biosimilar Development), Guest Column, March 26, 2019.
• "Top Trends In The Biopharmaceutical Industry And Bioprocessing For 2019," BioProcess Online, Dec. 18, 2018; and also in Life Sciences Leader. Dec. 18, 2018.
• "Single-Use Bioprocessing Equipment Trends and Adoption by CMOs," BioPharm Intl., vol. 31, issue 11, p. 10-13, Nov. 2018.
• "Current Challenges in Bioprocess Development," Pharm. Tech., vol, 42, no. 3, p. 64-5, Nov. 2018.
• "Biopharma Market: An Inside Look: Survey results reveal how slow-motion trends are driving biopharma growth," Pharmaceutical Manufacturing, Nov. 15, 2018.
• "Biopharmaceutical Manufacturing is Shifting to Single-Use Systems. Are the Dinosaurs, the Large Stainless Steel Facilities, Becoming Extinct?," American Pharmaceutical Review, October 2018.
• "Worldwide Biopharmaceutical Manufacturing Capacity Analysis: Growth Continues Across the Board," BioProcess Intl.,, vol 6, no, 9, p. 20-25. Sept, 2018.
• "Fifteen Years of Progress: Biopharmaceutical Industry Survey Results," BioPharm Intl.,, vol 31, no, 7, p. 10-14. July 2018; and Pharmaceutical Technology, vol 42, no, 7, p. 56-59. July 2018.
• "Biopharma Manufacturing Markets: Biomanufacturing Contract Services and Supplies Markets Continue to Expand," Contract Pharma, May, 2018, p 46-49; also published in Trends in Biologics Manufacturing,, a Contract Pharma Ebook, Nov. 2018, p. 4-7.
• "Current Challenges in Bioprocesses Development," Pharm. Tech., 42 (3), 64-65 (2018); Reprinted in Improving Efficiencies in Biomanufacturing with Formulation Development and Continuous Processing Ebook.
• "eBook: The Commercial Expression Systems Market - What Has Changed in the Past Decade," BioProcess Intl., May 3, 2018.
• "New Microbiological Methods In Bioprocessing," BioProcess Online, April 11, 2018.
• "Biopharma CMO Consolidation: Opportunity or Obstacle?," Pharmaceutical Manufacturing, March 2018
• "Cell and Gene Therapies: Industry Faces Potential Capacity Shortages," Genetic Engineering & Biotechnology News (GEN), 37(20), Nov. 15, 2017.
• "Biosimilars Paving The Way For Cost-Effective Bioprocessing," Biosimilar Development, Aug. 23, 2017.
• "Overcoming The Manufacturing Hurdles Of Cell & Gene Therapy," Life Sciences Leader, Feb. 20, 2017.
• "Biosimilars and Biobetters: Impact on Biopharmaceutical Manufacturing and CMOs," in Biosimilars of Monoclonal Antibodies: A Practical Guide to Manufacturing, Preclinical, and Clinical Development, by Liu, C. and Morrow, J., Wiley, Dec. 2016.
• "Biosimilars Pipeline Analysis: Many Products, More Competition Coming", Biosimilar Development, July 26, 2016.
• "Future Manufacturing Strategies for Biosimilars," BioProcess International, May 2016, 14(5), p. 24-29
• "Biosimilars Outsourcing and Capacity," Contract Pharma, May 2016
• "Biosimilars and Biobetters: How Biosimilars and Biobetters Will Affect the Biopharma CMO Market," Pharmaceutical Processing, Jan. 1, 2013.
• "Biosimilars Improving Efficiency, Cost for All Biologics,," Contract Pharma, April 2015, p. 28-30.
• "Thirty Years of Upstream Productivity Improvements," BioProcess International, 14(2), Feb. 2015, p. 10-14.
• "Biosimilars Impacting CMO Capacity," Pharmaceutical Outsourcing, Jan./Feb. 2015, p. 22-16.
• "Biopharmaceutical Manufacturing: Historical and Future Trends in Titers, Yields, and Efficiency in Commercial-Scale Bioprocessing," BioProcessing J., 13(1), 13(4), Winter 2014/2015, p. 47-54.
• "Single-use Technologies in Biopharmaceutical Manufacturing: A 10-year Review of Trends and the Future," in Engineering in the Life Sciences, Wiley, May 2014, p. 238-243.
• "Continuous Bioprocessing and Perfusion:  Wider Adoption Coming as Bioprocessing Matures," BioProcessing J., 13(1), Spring 2014, p. 43-49.
• "Powders and Liquids:  Economics of Large-Scale Culture Media and Buffer Preparation are Changing," BioProcess International, 12(3), March 2014, p. 10-16.
• "Bioprocess Advances Drive Vaccine Manufacturing in Developing Countries," BioProcess International, 12(2), Feb. 2014, p. 10-15.
• "Biosimilars in the Rest of the World: Developments in Lesser-Regulated Countries," BioProcessing J., 12(4), Winter 2013/2014, p. 41-47
• "Innovation in Stainless Steel Bioprocessing," Life Sciences Leader, Nov. 2013, p. 20-22. '
• "Biosimilars and Biobetters," PharmaPro: News, Views, & Technology for the Industry, Jan. 14, 2013.
• "Biopharma Nomenclature:  Citizen Petition Requests Biopharmaceutical Names and Information Be Disclosed by FDA," Contract Pharma, Sept. 2013, back page [guest editorial].
• "An Analysis of the U.S. Biosimilars Development Pipeline and Likely Market Evolution," BioProcess International, vol. 11, no. 6, Biosimilars supplement, June 2013, pp. 16-23.
• "Introduction to Continuous Manufacturing: Technology Landscape and Trends," in Continuous Bioprocessing: Current Practice and Future Potential, Refine Technology, June 2013, p. 3-8.
• "The Biosimilars Pipeline and U.S. Market Evolution: A 2013 Assessment," in Biopharmaceutical R&D Statistical Sourcebook 2013/2014, Parexel, June 2013, p. 113-116.
• "FDA Biopharmaceutical Product Approvals and Trends in 2012," BioProcess International, vol. 11, no. 3, March 2013, pp. 18-27.
• "Fill-Finish Innovation: Showing Sparks of Life," Contract Pharma, vol. 15, no. 1, p. 40-46, Jan.-Feb. 2013 [publisher did not include article in this issue's index].
• "Biosimilars and Biobetters," PharmaPro: News, Views, & Technology for the Industry, Jan. 14, 2013.
• "Biosimilars and Biobetters: How Biosimilars and Biobetters Will Affect the Biopharma CMO Market," Pharmaceutical Processing, Jan. 1, 2013.
• "Upstream Single-Use Bioprocessing Systems:  Future Market Trends and Growth Assessment," BioProcess International, Feb. 2012.
• "Top 50 Biologics" [by 2010 revenue], Contract Pharma, July/Aug. 2011.
• "Nomenclature of Biosimilars Will Be Highly Controversial, BioProcess International, June 2011, 28-32.
• "A History of Approved Recombinant Cell Culture Products, 1980-2010," BioProcess International, vol. 7, no. 11, Dec. 2009, large wallchart/poster insert.
• "(Re)defining Biopharmaceutical" Nature Biotechnology, July 2008, 26(7), p.  743-751.
• "Expression Systems for Process and Product Development: A Perspective on Opportunities for Innovator and Follow-on Product Developers," BioProcess International, vol.  6, issue 6, suppl.  4, Success Stories in Protein Expression, p. 4-9, June 2008 [supplement lead article]. 
• "Biopharmaceuticals: Lack of Information Disclosure Confounds Public Trust, Particularly in the Context of Biosimilars," BioWorld Perspectives, vol.  2, issue 18, May 1, 2008.
• "Paucity of Biopharma Approvals Raises Alarm: Lower Numbers, Novelty and Economic Impact Indicate Problems," Genetic Engineering & Biotechnology News (GEN), March 15, 2008
• "How Big is the World Market for Biopharmaceuticals? It All Depends How You Define Biopharmaceutical," in Friedman, Y., Best Practices in Biotechnology Business Development, Logo Press, p.  175-85, 2008.
• "What Is a Generic Biopharmaceutical? Biogeneric? Follow-On Protein? Biosimilar? Follow-On Biologic?" Part 1: Introduction and Basic Paradigms - BioProcess International, March 2007.
• "What Is a Generic Biopharmaceutical? Biogeneric? Follow-On Protein? Biosimilar? Follow-On Biologic?" Part 2: Information, Nomenclature, Perceptions, and the Market - BioProcess International, May 2007.
• Biopharmaceutical Approvals Review - Genetic Engineering News, Aug.  1, 2006
• What is a Biopharmaceutical, Part 1: (Bio)Technology-Based Definitions - BioExecutive, March 2005.
• What is a Biopharmaceutical, Part 2: Company and Industry Definitions - BioExecutive, May 2005.

Mr.  Rader's main Web sites:

• Biosimilars and Biobetters Pipeline Directory (www.biosimilarspipeline.com)
• BIOPHARMA:  Biopharmaceutical Products in the U.S.  and European Markets (www.Biopharma.com)
• U.S. BIOPHARMACOPEIA Registry of Biopharmaceutical Products (www.biopharmacopeia.com)

Further information: Resume

Ronald A. Rader
President
Biotechnology Information Institute
1700 Rockville Pike, Suite 400
Rockville, MD 20852
Phone: 301-424-0255
E-mail: domains@biopharma.com
Phone is the preferred contact method.